Legal Representation
Attorney
Shannon T. Vale
USPTO Deadlines
Next Deadline
25 days remaining
Final Refusal E-Mailed
Due Date
August 07, 2025
Extension Available
Until November 07, 2025
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| May 7, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| May 7, 2025 | GNFR | O | FINAL REFUSAL E-MAILED |
| May 7, 2025 | CNFR | W | SU - FINAL REFUSAL - WRITTEN |
| Apr 17, 2025 | ALIE | A | ASSIGNED TO LIE |
| Apr 17, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Apr 17, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 28, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 15, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jan 15, 2025 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Jan 15, 2025 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Jan 3, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Jan 2, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| May 13, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| May 13, 2024 | IUAF | S | USE AMENDMENT FILED |
| Nov 18, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Nov 17, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Nov 17, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Nov 10, 2023 | EXT5 | S | SOU EXTENSION 5 FILED |
| Nov 10, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 10, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| May 8, 2023 | EX4G | S | SOU EXTENSION 4 GRANTED |
| May 8, 2023 | EXT4 | S | SOU EXTENSION 4 FILED |
| May 8, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 14, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Nov 8, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Nov 4, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Nov 4, 2022 | EXT3 | S | SOU EXTENSION 3 FILED |
| Nov 4, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 11, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| May 9, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED |
| May 9, 2022 | EXT2 | S | SOU EXTENSION 2 FILED |
| May 9, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 7, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Dec 7, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Dec 7, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Nov 13, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Nov 11, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Nov 11, 2021 | EXT1 | S | SOU EXTENSION 1 FILED |
| Nov 11, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 11, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Mar 16, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Mar 16, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Feb 24, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Feb 8, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Feb 8, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Feb 8, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Feb 8, 2021 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Feb 8, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Feb 4, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 11, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetic foot ulcers; Pharmaceutical preparations for accelerating healing of human tissue; Therapeutic gels intended for topical use on skin and mucous membranes, intended to accelerate the healing of skin surface wounds and diabetic foot ulcers; Pharmaceuticals for the treatment of acute radiation syndrome; Pharmaceuticals for the treatment of COVID-19; Pharmaceutical products for the prevention and treatment of Degenerative Brain Diseases and Traumatic Brain Injury (TBI)
First Use Anywhere:
20190600
First Use in Commerce:
20190600
Additional Information
Pseudo Mark
CHRYSALIS BIO THERAPEUTICS
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOTHERAPEUTICS"
USPTO Documents
Loading USPTO documents...